Lantern Pharma (LTRN) Expected to Release Quarterly Earnings on Wednesday

Lantern Pharma (NASDAQ:LTRN) is projected to issue its Q3 2026 resultson Wednesday, November 11th. Analysts expect Lantern Pharma to post earnings of ($0.35) per share for the quarter. Interested persons may review the information on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 12, 2026 at 9:00 AM ET.

Lantern Pharma (NASDAQ:LTRN) last issued its earnings results on Friday, August 14th. The company reported ($0.57) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.19).

Lantern Pharma Price Performance

Shares of LTRN opened at $0.62 on Wednesday. The stock has a market cap of $9.20 million, a PE ratio of -0.39 and a beta of 2.48. The stock’s 50-day moving average is $1.23 and its two-hundred day moving average is $2.45. Lantern Pharma has a 12 month low of $0.58 and a 12 month high of $4.34.

Wall Street Analyst Weigh In

Several research firms have recently commented on LTRN. Wall Street Zen cut Lantern Pharma from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Lantern Pharma in a research report on Tuesday, October 27th. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the stock has a consensus rating of “Sell”.

About Lantern Pharma

Lantern Pharma, Inc is a clinical-stage biopharmaceutical company focused on developing precision cancer therapies. The company combines artificial intelligence, machine learning and genomic analysis to identify drug candidates, patient populations and biomarkers that may support more targeted oncology treatments.

Lantern Pharma’s technology platform, RADR, is designed to analyze large volumes of biological, genomic and clinical data to help accelerate drug discovery and development. The platform is used to evaluate existing and novel therapeutic compounds, identify potential mechanisms of action and support the development of biomarker-driven clinical programs.

The company’s oncology pipeline has included investigational therapies for solid tumors and hematologic cancers, including programs such as LP-184 and LP-284.